Who are Lévétiracetam's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Keppra, Topiramate-Implant, Lacosamide - rapid titration 1, LEV, Topiramate monotherapy, Oral levetiracetam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/l-v-tiracetam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Lévétiracetam — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lévétiracetam (Lévétiracetam) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiepileptic agent. Area: Neurology.

phase 3 Antiepileptic agent SV2A (synaptic vesicle protein 2A) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Lévétiracetam (Lévétiracetam) — Hospices Civils de Lyon. Levetiracetam reduces neuronal excitability by binding to synaptic vesicle protein SV2A, thereby modulating neurotransmitter release and preventing seizure propagation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lévétiracetam TARGET	Lévétiracetam	Hospices Civils de Lyon	phase 3	Antiepileptic agent	SV2A (synaptic vesicle protein 2A)
Keppra	levetiracetam	Generic (originally UCB Pharma)	marketed	Antiepileptic agent	Synaptic vesicle protein SV2A	1999-11-30
Topiramate-Implant	Topiramate-Implant	University of Sao Paulo	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor, sodium channels, glutamate receptors
Lacosamide - rapid titration 1	Lacosamide - rapid titration 1	Seoul National University Hospital	marketed	Antiepileptic agent (sodium channel modulator)	Voltage-gated sodium channels (slow inactivation enhancer)
LEV	LEV	GlaxoSmithKline	marketed	Antiepileptic agent	SV2A (synaptic vesicle glycoprotein 2A)
Topiramate monotherapy	Topiramate monotherapy	Johnson & Johnson Taiwan Ltd	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor; voltage-gated sodium channels
Oral levetiracetam	Oral levetiracetam	Children's Hospital of Fudan University	marketed	Antiepileptic agent	SV2A (synaptic vesicle protein 2A)

Recent regulatory actions (last 90 days)

2026-05-08 — Keppra · FDA · approved · US · Generic (originally UCB Pharma)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-09-03 — Keppra · 8163306 · Formulation · US
2027-10-31 — Keppra · 8431156 · Formulation · US
2027-10-31 — Keppra · 8470367 · Formulation · US
2028-09-17 — Keppra · 7858122 · Formulation · US
2031-06-07 — Keppra · 8802142 · Formulation · US
2031-12-07 — Keppra · 8802142*PED · Compound · US
2034-03-14 — Keppra · 11160786 · Formulation · US
2034-03-14 — Keppra · 9669009 · Method of Use · US
2034-03-14 — Keppra · 9339489 · Formulation · US

Sponsor landscape (Antiepileptic agent class)

Children's Hospital of Fudan University · 1 drug in this class
Generic (originally UCB Pharma) · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
Mario Negri Institute for Pharmacological Research · 1 drug in this class
Richard H. Haas · 1 drug in this class
ayesha tariq · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lévétiracetam — Competitive Intelligence Brief. https://druglandscape.com/ci/l-v-tiracetam. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing